查看文章

Please note: This work was supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health. Dr. Fayad has received consulting fees from Alexion and GlaxoSmithKline; has received research funding from Daiichi-Sankyo, Amgen, Bristol-Myers Squibb, and Siemens Healthineers; and has received financial compensation as a board member and advisor to and owns equity as a co-founder of Trained Therapeutix Discovery. Dr. Nadkarni has received financial compensation as a consultant and Advisory Board member for and owns equity in RenalytixAI; is a scientific co-founder of RenalytixAI and Pensieve Health; has received operational funding from Goldfinch Bio; and has received consulting fees from BioVie Inc., AstraZeneca, Reata, and GLG consulting in the past 3 years. All other authors have reported that they have no relationships relevant to the contents of …